A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Study summary

A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedRucaparib

The study team can explain what participation involves.

Who it may be forSolid Tumor

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 2, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?19 U.S. locations

Locations may change over time.

Who runs it?pharmaand GmbH

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: pharmaand GmbH
Interventions being studied: Drug: Rucaparib

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Key
Unresectable, locally advanced or metastatic solid tumor and relapsed/progressive disease
Measurable disease per RECIST v1.1 or modified RECIST v1.1 and PCWG3 (for prostate cancer)
Have a deleterious mutation (germline or somatic) in BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B. Note: Breast cancer patients that are HER2 negative and have germline BRCA1 or BRCA2 mutations AND patients with epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or metastatic castration-resistant prostate cancer with BRCA1 or BRCA2 mutations are ineligible for this trial.
At least one prior line of therapy extending overall survival or standard of care therapy for advanced disease. Note: Some tumor types have specific inclusion/

Reasons someone may not be able to joinExclusion criteria

for previous treatments.
ECOG 0 or 1
Tumor tissue available for genomic analysis, or must be willing to have a biopsy if no archival tumor tissue available
Adequate organ function
Life expectancy of 4 months Key

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

UCLA Medicine Hematology and OncologyLos Angeles, California
UCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco, California
Florida Cancer SpecialistsFort Myers, Florida
Florida Cancer SpecialistsSt. Petersburg, Florida
H. Lee Moffitt Cancer Center & Research InstituteTampa, Florida
Robert H. Lurie Comprehensive Cancer Center of Northwestern UniversityChicago, Illinois
University of Iowa Hospital and ClinicsIowa City, Iowa
Beth Israel Deaconess Medical Cancer Surgical PavilionBoston, Massachusetts
Dana Farber Cancer InstituteBoston, Massachusetts
Columbia University Irving Medical CenterNew York, New York
New York Cancer and Blood SpecialistsPort Jefferson Station, New York
New York Cancer And Blood SpecialistsThe Bronx, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 2, 2023. Always confirm current availability with the study team.

View original record ↗